查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1746516

日本溃疡性结肠炎市场报告（按类型、疾病类型、分子类型、药物类型、给药途径、配销通路和地区）2025-2033

Japan Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 120 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024年，日本溃疡性结肠炎市场规模达3.46亿美元。展望未来， IMARC Group预计到2033年，市场规模将达到5.625亿美元，2025-2033年期间的复合年增长率（CAGR）为5.13%。日本溃疡性结肠炎盛行率的上升、医疗基础设施的完善和医疗技术的进步、研发计划的不断推进、技术的快速进步以及医疗机构和患者权益组织不断加强的公众意识提升，是推动市场发展的关键因素。

溃疡性结肠炎是一种发炎性肠道疾病，会对大肠和直肠内壁造成不利影响。其症状多样，如持续性腹泻、直肠出血、腹痛、疲劳和体重减轻。溃疡性结肠炎疑似由环境因素、遗传易感性和过度活跃的免疫反应共同引起。其诊断透过多项检测进行，例如粪便样本采集、血液检查、大肠镜检查和影像学检查。溃疡性结肠炎的治疗方法包括抗发炎药物、免疫抑制剂，在病情较为严重的情况下，也可进行手术介入。这些治疗方法具有许多益处，包括缓解症状、减少发作频率、降低结肠癌等併发症的风险。此外，这些治疗方法还能促进营养吸收和消化功能，进而改善患者的整体生活品质。此外，这些疗法以严谨的科学研究为后盾，为患者带来了许多益处，例如持久的缓解期和减少住院需求。

日本溃疡性结肠炎市场趋势：

在日本，溃疡性结肠炎的发生率不断上升是推动市场成长的主要因素之一。此外，日本拥有高品质的医疗基础设施和先进的医疗技术，能够对疾病进行精准诊断和有效管理，这为市场成长创造了积极的前景。此外，在政府以拨款和政策形式提供的支持下，製药业日益重视新药和新疗法的研发 (R&D)，也支撑了市场的成长。此外，快速的技术进步，例如人工智慧 (AI) 融入诊断程序和资料分析，使医疗保健提供者能够制定个人化的治疗方案，也正在促进市场的成长。此外，远距医疗平台的日益普及，使得医病互动更加频繁和便捷，也促进了市场的成长。此外，医疗机构和患者权益团体不断加强的公众意识提升活动，提高了人们对该疾病的关注度，并促进了早期诊断，预计将推动市场的成长。此外，日本老龄人口不断增长，导致溃疡性结肠炎发病率上升，这也刺激了市场成长。此外，製药公司与学术机构之间日益加强的合作关係，促进了药物研发的创新，也对市场成长产生了正面的影响。同时，新型生物製剂的推出，带来了疗效显着、副作用更少、缓解期更长、就诊次数更少等优势，也为市场成长提供了强劲动力。此外，各公司越来越重视病患教育和依从性计划，以改善长期治疗效果，这为全国各地的市场带来了丰厚的成长机会。

日本溃疡性结肠炎市场区隔：

类型洞察：

  • 轻度溃疡性结肠炎
  • 中度溃疡性结肠炎
  • 严重溃疡性结肠炎

疾病类型洞察：

  • 溃疡性直肠炎
  • 直肠乙状结肠炎
  • 左侧结肠炎
  • 全结肠炎或普遍性结肠炎
  • 暴发性结肠炎

分子类型洞察：

  • 小分子
  • 生物製剂

药物类型洞察：

  • 抗发炎药物
  • 抗TNF生物製剂
  • 免疫抑制剂
  • 钙调神经磷酸酶抑制剂
  • 其他的

给药途径洞察：

  • 口服
  • 注射剂

配销通路洞察：

  • 医院药房
  • 零售药局
  • 药局
  • 其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本溃疡性结肠炎市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本溃疡性结肠炎市场有何影响？
  • 日本溃疡性结肠炎市场依类型分为哪些类型？
  • 日本溃疡性结肠炎市场如何根据疾病类型划分？
  • 根据分子类型，日本溃疡性结肠炎市场是如何分類的？
  • 根据药物类型，日本溃疡性结肠炎市场是如何分類的？
  • 根据给药途径，日本溃疡性结肠炎市场是如何分布的？
  • 日本溃疡性结肠炎市场根据配销通路的分布如何？
  • 日本溃疡性结肠炎市场的价值链分为哪些阶段？
  • 日本溃疡性结肠炎的主要驱动因素和挑战是什么？
  • 日本溃疡性结肠炎市场的结构是怎么样的？主要参与者是谁？
  • 日本溃疡性结肠炎市场的竞争程度如何？

本报告回答的关键问题：

  • 日本溃疡性结肠炎市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本溃疡性结肠炎市场有何影响？
  • 日本溃疡性结肠炎市场依类型分为哪些类型？
  • 日本溃疡性结肠炎市场如何根据疾病类型划分？
  • 根据分子类型，日本溃疡性结肠炎市场是如何分類的？
  • 根据药物类型，日本溃疡性结肠炎市场是如何分類的？
  • 根据给药途径，日本溃疡性结肠炎市场是如何分布的？
  • 日本溃疡性结肠炎市场根据配销通路的分布如何？
  • 日本溃疡性结肠炎市场的价值链分为哪些阶段？
  • 日本溃疡性结肠炎的主要驱动因素和挑战是什么？
  • 日本溃疡性结肠炎市场的结构是怎么样的？主要参与者是谁？
  • 日本溃疡性结肠炎市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本溃疡性结肠炎市场 - 简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本溃疡性结肠炎市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本溃疡性结肠炎市场-分类：依类型

  • 轻度溃疡性结肠炎
    • 概述
  • 中度溃疡性结肠炎
    • 概述
  • 严重溃疡性结肠炎
    • 概述

第 7 章：日本溃疡性结肠炎市场 - 细分：依疾病类型

  • 溃疡性直肠炎
    • 概述
  • 直肠乙状结肠炎
    • 概述
  • 左侧结肠炎
    • 概述
  • 全结肠炎或普遍性结肠炎
    • 概述
  • 暴发性结肠炎
    • 概述

第 8 章：日本溃疡性结肠炎市场 - 细分：按分子类型

  • 小分子
    • 概述
  • 生物製剂
    • 概述

第九章：日本溃疡性结肠炎市场-细分：依药物类型

  • 抗发炎药物
    • 概述
  • 抗TNF生物製剂
    • 概述
  • 免疫抑制剂
    • 概述
  • 钙调神经磷酸酶抑制剂
    • 概述
  • 其他的

第 10 章：日本溃疡性结肠炎市场 - 细分：依给药途径

  • 口服
    • 概述
  • 注射剂
    • 概述

第 11 章：日本溃疡性结肠炎市场 - 细分：按配销通路

  • 医院药房
    • 概述
  • 零售药局
    • 概述
  • 药局
    • 概述
  • 其他的

第 12 章：日本溃疡性结肠炎市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第十三章：关键参与者简介

  • Company A
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 14 章：日本溃疡性结肠炎市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 15 章：附录

简介目录
Product Code: SR112025A19356

The Japan ulcerative colitis market size reached USD 346.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 562.5 Million by 2033, exhibiting a growth rate (CAGR) of 5.13% during 2025-2033. The increasing prevalence of ulcerative colitis in Japan, rising healthcare infrastructure and advanced medical technologies, growing research and development (R&D) initiatives, rapid technological advancements, and heightened public awareness initiatives by healthcare organizations and patient advocacy groups represent some of the key factors driving the market.

Ulcerative colitis refers to an inflammatory bowel disease that adversely affects the lining of the large intestine and rectum. It exhibits various symptoms, such as persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. Ulcerative colitis is suspected to be caused by a combination of environmental factors, genetic predisposition, and an overactive immune response. It is diagnosed through multiple tests, such as stool samples, blood tests, colonoscopy, and imaging studies. Ulcerative colitis is treated using anti-inflammatory medications, immunosuppressants, and, in more severe cases, surgical intervention. The treatments offer numerous benefits, including symptom relief, decreased frequency of flare-ups, and reduced risk of complications, such as colon cancer. They also improve the overall quality of life for patients by enabling better nutrient absorption and digestive function. Moreover, the therapies, backed by rigorous scientific research, provide patients with substantial advantages, such as long-lasting remission periods and a decreased need for hospitalization.

Japan Ulcerative Colitis Market Trends:

The increasing prevalence of ulcerative colitis in Japan is one of the major factors contributing to the market growth. Moreover, the presence of a high-quality healthcare infrastructure and advanced medical technologies, allowing for precise diagnosis and effective management of the disease, is creating a positive outlook for the market growth. Additionally, the growing focus of the pharmaceutical industry on research and development (R&D) of new drugs and therapies, aided by government support in the form of grants and policies, is supporting the market growth. Along with this, rapid technological advancements, such as the integration of artificial intelligence (AI) in diagnostic procedures and data analytics, enabling healthcare providers to develop personalized treatment plans, are enhancing the market growth. In addition to this, the increasing adoption of telemedicine platforms, allowing for more frequent and convenient patient-doctor interactions, is bolstering the market growth. Besides this, the rising public awareness initiatives by healthcare organizations and patient advocacy groups, raising the profile of the disease and leading to earlier diagnosis, are anticipated to drive the market growth. Apart from this, the growing geriatric population in Japan, resulting in heightened incidences of ulcerative colitis, is also stimulating the market growth. Furthermore, the rising partnerships between pharmaceutical companies and academic institutions, fostering innovation in drug development and research, are positively influencing the market growth. In line with this, the introduction of new biologic drugs, offering effective results, fewer side effects, longer remission periods, and reduced hospital visits, are providing a thrust to the market growth. Moreover, the increasing focus by companies on patient education and compliance programs to improve long-term treatment outcomes is offering lucrative growth opportunities for the market across the country.

Japan Ulcerative Colitis Market Segmentation:

Type Insights:

  • Mild UC
  • Moderate UC
  • Severe UC

Disease Type Insights:

  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis

Molecule Type Insights:

  • Small Molecules
  • Biologics

Drug Type Insights:

  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

Route of Administration Insights:

  • Oral
  • Injectable

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan ulcerative colitis market?
  • What is the breakup of the Japan ulcerative colitis market on the basis of type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of disease type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of molecule type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of drug type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of route of administration?
  • What is the breakup of the Japan ulcerative colitis market on the basis of distribution channel?
  • What are the various stages in the value chain of the Japan ulcerative colitis market?
  • What are the key driving factors and challenges in the Japan ulcerative colitis?
  • What is the structure of the Japan ulcerative colitis market and who are the key players?
  • What is the degree of competition in the Japan ulcerative colitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Ulcerative Colitis Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Ulcerative Colitis Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Ulcerative Colitis Market - Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Moderate UC
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Severe UC
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)

7 Japan Ulcerative Colitis Market - Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Proctosigmoiditis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Left-sided Colitis
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2019-2024)
    • 7.4.3 Market Forecast (2025-2033)
  • 7.5 Fulminant Colitis
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2019-2024)
    • 7.5.3 Market Forecast (2025-2033)

8 Japan Ulcerative Colitis Market - Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Biologics
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)

9 Japan Ulcerative Colitis Market - Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2019-2024)
    • 9.1.3 Market Forecast (2025-2033)
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2019-2024)
    • 9.2.3 Market Forecast (2025-2033)
  • 9.3 Immunosuppressant
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2019-2024)
    • 9.3.3 Market Forecast (2025-2033)
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2019-2024)
    • 9.4.3 Market Forecast (2025-2033)
  • 9.5 Others
    • 9.5.1 Historical and Current Market Trends (2019-2024)
    • 9.5.2 Market Forecast (2025-2033)

10 Japan Ulcerative Colitis Market - Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2019-2024)
    • 10.1.3 Market Forecast (2025-2033)
  • 10.2 Injectable
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2019-2024)
    • 10.2.3 Market Forecast (2025-2033)

11 Japan Ulcerative Colitis Market - Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Historical and Current Market Trends (2019-2024)
    • 11.1.3 Market Forecast (2025-2033)
  • 11.2 Retail Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Historical and Current Market Trends (2019-2024)
    • 11.2.3 Market Forecast (2025-2033)
  • 11.3 Drug Store
    • 11.3.1 Overview
    • 11.3.2 Historical and Current Market Trends (2019-2024)
    • 11.3.3 Market Forecast (2025-2033)
  • 11.4 Others
    • 11.4.1 Historical and Current Market Trends (2019-2024)
    • 11.4.2 Market Forecast (2025-2033)

12 Japan Ulcerative Colitis Market - Competitive Landscape

  • 12.1 Overview
  • 12.2 Market Structure
  • 12.3 Market Player Positioning
  • 12.4 Top Winning Strategies
  • 12.5 Competitive Dashboard
  • 12.6 Company Evaluation Quadrant

13 Profiles of Key Players

  • 13.1 Company A
    • 13.1.1 Business Overview
    • 13.1.2 Services Offered
    • 13.1.3 Business Strategies
    • 13.1.4 SWOT Analysis
    • 13.1.5 Major News and Events
  • 13.2 Company B
    • 13.2.1 Business Overview
    • 13.2.2 Services Offered
    • 13.2.3 Business Strategies
    • 13.2.4 SWOT Analysis
    • 13.2.5 Major News and Events
  • 13.3 Company C
    • 13.3.1 Business Overview
    • 13.3.2 Services Offered
    • 13.3.3 Business Strategies
    • 13.3.4 SWOT Analysis
    • 13.3.5 Major News and Events
  • 13.4 Company D
    • 13.4.1 Business Overview
    • 13.4.2 Services Offered
    • 13.4.3 Business Strategies
    • 13.4.4 SWOT Analysis
    • 13.4.5 Major News and Events
  • 13.5 Company E
    • 13.5.1 Business Overview
    • 13.5.2 Services Offered
    • 13.5.3 Business Strategies
    • 13.5.4 SWOT Analysis
    • 13.5.5 Major News and Events

14 Japan Ulcerative Colitis Market - Industry Analysis

  • 14.1 Drivers, Restraints, and Opportunities
    • 14.1.1 Overview
    • 14.1.2 Drivers
    • 14.1.3 Restraints
    • 14.1.4 Opportunities
  • 14.2 Porters Five Forces Analysis
    • 14.2.1 Overview
    • 14.2.2 Bargaining Power of Buyers
    • 14.2.3 Bargaining Power of Suppliers
    • 14.2.4 Degree of Competition
    • 14.2.5 Threat of New Entrants
    • 14.2.6 Threat of Substitutes
  • 14.3 Value Chain Analysis

15 Appendix